Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients
Neuromuscular Blockade, Critical Illness, Neurologic Findings
About this trial
This is an interventional treatment trial for Neuromuscular Blockade focused on measuring Reversal of neuromuscular blockade, Neurologic assessment, Endotracheal intubation, Critically ill patient
Eligibility Criteria
Inclusion Criteria: Adult patients 19 years of age or older who were intubated after admission to the intensive care unit. Exclusion Criteria: Patients younger than 19 years of age Patients who are not neurologically evaluable or have concomitant neurologic dysfunction Patients with neuromuscular disorder Patients with a history of drug allergic reactions to sugammadex or neostigmine Patients taking or planning to take toremifene, fusidic acid, or hormonal contraceptives
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
No Intervention
Sugammadex group
Neostigmine group
Control group
Patient is intubated with etomidate 0.1~0.2mg/kg and rocuronium 1mg/kg. 30 minutes after rocuronium administration, patient is administered sugammadex 1mg/kg. Glasgow coma scale as neurologic assessment is assessed at 10-minute intervals before intubation, and at 5-minute intervals up to 30 minutes after administration of sugammadex. After 30 minutes, the assessments are conducted at 10-minute intervals. Additionally, if the patient spontaneously opens their eyes, the GCS is assessed at that specific moment. The GCS evaluation continues until the patient reaches a point of responsiveness, indicated by a Motor score of 6 on the GCS.
Patient is intubated with etomidate 0.1~0.2mg/kg and rocuronium 1mg/kg. 30 minutes after rocuronium administration, patient is administered neostigmine 0.05mg/kg + glycopyrrolate 0.01mg/kg. Glasgow coma scale as neurologic assessment is assessed at 10-minute intervals before intubation, and at 5-minute intervals up to 30 minutes after administration of neostigmine. After 30 minutes, the assessments are conducted at 10-minute intervals. Additionally, if the patient spontaneously opens their eyes, the GCS is assessed at that specific moment. The GCS evaluation continues until the patient reaches a point of responsiveness, indicated by a Motor score of 6 on the GCS.
Patient is intubated with etomidate 0.1~0.2mg/kg and rocuronium 1mg/kg. Glasgow coma scale as neurologic assessment is assessed at 10-minute intervals before intubation, and at 5-minute intervals up to 60 minutes after intubation. After 60 minutes, the assessments are conducted at 10-minute intervals. Additionally, if the patient spontaneously opens their eyes, the GCS is assessed at that specific moment. The GCS evaluation continues until the patient reaches a point of responsiveness, indicated by a Motor score of 6 on the GCS.